Oculis Closes Phase III Eye Drop Trial Due to Third-Party Administrative Error - BioSpace
Oculis halts Phase III trial of OCS-01 due to third-party error, but FDA accepts data from other trials for NDA submission in Q1 2025. OCS-01 is developed for post-op inflammation, pain, and DME.
Highlighted Terms
Related News
Oculis Closes Phase III Eye Drop Trial Due to Third-Party Administrative Error - BioSpace
Oculis halts Phase III trial of OCS-01 due to third-party error, but FDA accepts data from other trials for NDA submission in Q1 2025. OCS-01 is developed for post-op inflammation, pain, and DME.